Lilly to buy startup Ajax in bid for a better JAK drug
Summary
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other d...
Description
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other d...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source